Table 3.
Univariate and Multivariate Predictors of Overall Survival in the Whole Series (n = 106)
| uHR | CI 95% | P-value | aHR | CI 95% | P-value | ||
|---|---|---|---|---|---|---|---|
| Parameters | |||||||
| Sex | Female | 1 (ref) | |||||
| Male | 2.47 | 0.68–10.32 | .166 | ||||
| Age, year | ≤40 | 1 (ref) | |||||
| > 40 | 1.58 | 0.53–4.73 | .409 | ||||
| Preoperative KPS score | > 70 | 1 (ref) | 1 (ref) | ||||
| ≤70 | 35.71 | 5.90–216.02 | <.0001 | 10.64 | 1.66–68.29 | .013 | |
| Corpus callosum involvement | No | 1 (ref) | |||||
| Yes | 1.92 | 0.59–6.14 | .272 | ||||
| Glioma location | Frontal | 1 (ref) | |||||
| Temporal | 1.37 | 0.38–4.95 | .625 | ||||
| Insular | 1.78 | 0.48–6.53 | .381 | ||||
| Parietal | 1.08 | 0.23–4.87 | .921 | ||||
| Glioma side location | Left | 1 (ref) | |||||
| Right | 1.03 | 0.35–3.04 | .948 | ||||
| Tumor volume, cc | <45 | 1 (ref) | |||||
| ≥45 | 2.10 | 0.65–6.75 | .211 | ||||
| Hyperperfusion | No | 1 (ref) | |||||
| Yes | 2.19 | 0.68–7.04 | .419 | ||||
| Missing | N/A | ||||||
| Contrast enhancement | None | 1 (ref) | |||||
| Faint and patchy | 0.33 | 0.04–2.65 | .297 | ||||
| Nodular-like | 1.29 | 0.38–4.31 | .683 | ||||
| Ring-like | 2.11 | 0.26–17.19 | .486 | ||||
| Residual tumor, cm3 | Per unit | 1.03 | 1.01–1.05 | .003 | 1.02 | 1.00–1.04 | .023 |
| Histo-molecular diagnosis | Oligodendroglioma | 1 (ref) | 1 (ref) | ||||
| Astrocytoma | 6.89 | 1.53–31.02 | .012 | 5.26 | 1.12–24.66 | .035 | |
| Oncological treatment | Surgery only | 1 (ref) | |||||
| Surgery + Radio-chemotherapy | 2.73 | 0.35–21.03 | .335 |
aHR, adjusted hazard ratio; CI, confidence interval; CHT, chemotherapy; KPS, Karnofsky Performance Status; RT, Radiotherapy; uHR, unadjusted hazard ratio.
Unadjusted hazard ratios by log-rank tests and adjusted hazard ratios by Cox proportional hazards model.
P-values in bold are significant.